John Rex
InvestorOperating Partner at Advent Life Sciences
About
John Rex joined Advent Life Sciences in 2014 and previously led AstraZeneca's antibiotic development group, later moving to full-time consulting after AstraZeneca's development pipeline was sold to Pfizer in 2016. He served a four-year term as the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee and currently is Chief Medical Officer of F2G Ltd. He holds an MD from Baylor College of Medicine, is board-certified in Internal Medicine and Infectious Diseases, and was previously Professor of Medicine at UT Medical School-Houston.
Contact· self-published, not guessed
Invests in
Biotech
Colleagues at Advent Life Sciences
Alain Huriez
Venture Partner at Advent Life Sciences
Alan Walts
Venture Partner at Advent Life Sciences
Andrea Beesley
Team Assistant at Advent Life Sciences
Bonita Theara
Executive Assistant at Advent Life Sciences
Dominic Schmidt
General Partner at Advent Life Sciences
Don Drakeman
Distinguished Research Professor, biotech entrepreneur, and venture partner
Fraser Murray
Head of Scientific Evaluation at Advent Life Sciences
Gail Jermyn
Investor Relations Partner at Advent Life Sciences
Frequently asked questions
- Who is John Rex?
- John Rex joined Advent Life Sciences in 2014 and previously led AstraZeneca's antibiotic development group, later moving to full-time consulting after AstraZeneca's development pipeline was sold to Pfizer in 2016. He served a four-year term as the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee and currently is Chief Medical Officer of F2G Ltd. He holds an MD from Baylor College of Medicine, is board-certified in Internal Medicine and Infectious Diseases, and was previously Professor of Medicine at UT Medical School-Houston.
- Where does John Rex work?
- John Rex is Operating Partner at Advent Life Sciences.
- What does John Rex invest in?
- John Rex invests in Biotech.